- Home
- NEA vs ARQT Comparison
NEA vs ARQT Comparison
Compare NEA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEA | ARQT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEA | ARQT |
|---|---|---|
| Price | $11.55 | $24.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | N/A | $29.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $10.53 | $12.42 |
| 52 Week High | $11.90 | $31.77 |
Technical Indicators
Market Signals| Indicator | NEA | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 53.77 |
| Support Level | $11.46 | $22.56 |
| Resistance Level | $11.79 | $25.03 |
| Average True Range (ATR) | 0.14 | 0.93 |
| MACD | 0.05 | 0.23 |
| Stochastic Oscillator | 88.57 | 78.05 |
Price Performance
Historical ComparisonAbout NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.